Novo Nordisk Foundation, Open Philanthropy, and Bill & Melinda Gates Foundation Launch Initiative to Support New Antiviral Medicines for Future Pandemics

/in

COPENHAGEN – SAN FRANCISCO – SEATTLE. Today, the Novo Nordisk Foundation, Open Philanthropy, and the Bill & Melinda Gates Foundation announced an initial commitment of up to $90 million of coordinated funding toward Pandemic Antiviral Discovery (PAD), a new initiative to catalyze discovery and early development of antiviral medicines for future pandemics. With equitable access […]

Read more

Biocomposites to present data on STIMULAN® at American Academy of Orthopaedic Surgeons Annual Meeting

/in

Combination antibiotics released from STIMULAN completely kill antibiotic resistant biofilms STIMULAN is the only calcium matrix antibiotic carrier approved for use in bone and soft tissue in the EU, UK, Canada, and Saudi Arabia Keele, UK, 15 March 2022 – Biocomposites, an international medical devices company that engineers, manufactures and markets world leading products for use […]

Read more

Gadeta announces significant progress in advancing pipeline and TEG platform development

/in

Aim is to develop gamma delta (γδ) T-cell receptor (TCR)-based immunotherapies for solid tumors Ph1/2 update on lead product GDT002 as well as nomination of second pipeline program GDT201 Utrecht, Netherlands and Boston, Mass., 15 March 2022: Gadeta B.V. (‘Gadeta’), a clinical-stage company developing innovative, gamma delta (γδ) T-cell receptor (TCR)-based immunotherapies for every cancer […]

Read more

James Brady Joins Verona Pharma as Non-Executive Director

/in

LONDON and RALEIGH, N.C., March 14, 2022 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces Mr. James Brady has joined the board as a Non-Executive Director. Read more…

Read more

Versameb CEO Klaas Zuideveld to Present at the RNA Leaders World Congress

/in

Presentation demonstrates lead therapeutic candidate VMB-100 has the potential to address the unmet medical needs of patients suffering from Stress Urinary Incontinence Versameb AG (“Versameb”), a pre-clinical stage company focused on discovering and developing innovative RNA-based therapeutics, today announces that its leadership team will be attending the RNA Leaders World Congress, taking place on the 16-17th […]

Read more